Global Acute Myeloid Leukemia Market, By Disease type (Myeloblastic, Promyelocytic, Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Acute Myeloid Leukemia Market Analysis and Size
The global acute myeloid leukemia market is expected to witness significant growth during the forecast period. Among the different types of leukemia, acute lymphoblastic leukemia (ALL) is often witnessed in children and young adults, mainly in the age group of 2 to 5 years old; however, acute myeloid leukemia (AML) is more commonly seen in adults. Leukaemia occurrences vary among patients of varied sexes, ages and races and these disparities are related mainly with levels of environmental exposure as also genetic factors. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global acute myeloid leukemia market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Acute Myeloid Leukemia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease type (Myeloblastic, Promyelocytic, Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Jazz Pharmaceuticals, Inc. (U.K.), Alvogen (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan)
|
|
Market Opportunities
|
|
Market Definition
Acute myeloid leukemia is a kind of haematological cancer that originates from blood-forming cells of the bone marrow. In this type of leukemia, the abnormal white blood cells are formed rapidly and get gathered in the bone marrow and thus, eventually, it affects the healthy blood cells. Symptoms include easy bruising, fatigue, breathlessness, and bleeding. Increased risk factors such as carcinogens, bold disorders, and genetics push the market expansion. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Global Acute Myeloid Leukemia Market Dynamics
Drivers
- Increase in Geriatric Population
The geriatric population is expected to increase the patient population globally, which boots the market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. The possibility of getting infected with varied types of cancer also rises. This boost the market growth.
- Huge Prevalence of Acute Myeloid Leukemia
There were about 61,780 new cases of leukemia and 22,840 mortalities in the U.S. in the year 2019. The number of acute myeloid leukemia cases was projected at 21,450, wherein adults held a major portion of the patient population. The growing prevalence and increased mortality rate in the U.S. and other countries are building way for higher uptake of associated therapies. This factor boosts the market growth.
Opportunities
- Surge in usage in Hospitals
Hospitals and specialty clinics are the biggest consumer of the leukemia treatment market and it is growing because of the development of more and more hospitals. In addition to this, healthcare companies are also launching new and improved formulations of drugs for lowering the basal cell carcinoma cases.
- Increased Technological Advancements
Conventional options for this diseased condition are unable to control relapse and are linked with numerous side-effects such as tissue damage, nausea and loss of appetite. These issues are pushing the companies to focus on several advanced approaches such as serine-threonine protein kinases, stem cell transplant and pipeline drugs. There are several upcoming therapies such as immunotoxins, alkylating agents, farnesyltransferase inhibitors, FMS-like tyrosine kinase 3 inhibitors, monoclonal antibodies and multi-drug-resistant modulators that are going to contribute in the betterment of the patient condition. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained healthcare professionals who are unaware of the knowledge of the treatment process could curb the growth of the global acute myeloid leukemia market over a forecast period.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. Treatment methods such as chemotherapy, targeted therapy, immunotherapy are of high cost and seemed to boost the market growth.
This global acute myeloid leukemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global acute myeloid leukemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In January 2022, the US FDA granted the company orphan drug designation for its pipeline compound OM-301 for the treatment of acute myeloid leukemia (AML) developed by Oncolyze Inc.
- In December 2021, the European Commission granted Orphan Drug Designation to SNDX-5613. It is a highly selective oral menin inhibitor for the treatment of acute myeloid leukemia (AML) developed by Syndax Pharmaceuticals Inc.
Global Acute Myeloid Leukemia Market Scope
The global acute myeloid leukemia market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease type
- Myeloblastic
- Promyelocytic
- Myelomonocytic
Treatment Type
- Targeted Therapy
- Chemotherapy
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Immunotherapy
- Hormone Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Acute Myeloid Leukemia Market Regional Analysis/Insights
The global acute myeloid leukemia market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global acute myeloid leukemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the rise cases of acute myeloid leukemia and favourable government policies as well as advanced healthcare facilities.
Asia-Pacific dominates the market due to the increase government initiatives and rapidly increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Acute Myeloid Leukemia Market Share Analysis
The global acute myeloid leukemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global acute myeloid leukemia market.
Key players operating in the global acute myeloid leukemia market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Jazz Pharmaceuticals, Inc. (U.K.)
- Alvogen (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
SKU-
